Browse All

Current Filters

CLEAR FILTER x

TITLE

Eight-point Reliable Change on Symbol Digit Modalities Test with Ozanimod: Findings from the Phase 3 SUNBEAM and DAYBREAK Extension Trials

Safety Patterns over Time with Ozanimod During an Open-label Extension Trial in Patients with Relapsing Multiple Sclerosis

Safety and Efficacy of Ozanimod in Patients with Early Relapsing Multiple Sclerosis: 1-year Analysis of the ENLIGHTEN Study

Author:Naismith, Robert   Zivadinov, Robert   Morrow, Sarah   Bass, Ann   Obeidat, Ahmed   Riser, Emily   Wray, Sibyl   Cristofanilli, Massimiliano   Riolo, Jon   Thorpe, Andrew   Chaudhry, Burhan   Mohiuddin, Kamran   Cheng, Chun-Yen   DeLuca, John   

Session Name:P10: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 3  

Topic:Multiple Sclerosis  

Program Number:P10.014  

Author Institution:Washington University School of Medicine, St Louis, Missouri, Saint Louis, MO  Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, New York, Buffalo, NY  London Health Sciences Centre, University Hospital, University of Western Ontario, London, Ontario, Canada, and Department of Clinical Neurological Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada, London, ON, Canada  Neurology Center of San Antonio, San Antonio, Texas, San Antonio, TX  Department of Neurology, The Medical College of Wisconsin, Milwaukee, Wisconsin, Milwaukee, WI  Alabama Neurology Associates, Birmingham, Alabama, Birmingham, AL  Hope Neurology MS Center, Knoxville, Tennessee, Knoxville, TN  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Bristol Myers Squibb, Princeton, New Jersey, Amherst, NY  Kessler Foundation, West Orange, New Jersey, and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers - New Jersey Medical School, Newark, New Jersey, West Orange, NJ  

Brain Volume Changes Over 1 Year in Ozanimod-treated Patients with Early-relapsing Multiple Sclerosis: An Interim Analysis of the ENLIGHTEN Study

Author:Zivadinov, Robert   Naismith, Robert   Morrow, Sarah   Bass, Ann   Obeidat, Ahmed   Riser, Emily   Wray, Sibyl   Riolo, Jon   Chaudhry, Burhan   Thorpe, Andrew   Cheng, Chun-Yen   DeLuca, John   

Session Name:P11: Multiple Sclerosis: Epidemiology and Neuroimaging  

Topic:Multiple Sclerosis  

Program Number:P11.017  

Author Institution:Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, New York, Buffalo, NY  Washington University School of Medicine, St Louis, Missouri, Saint Louis, MO  London Health Sciences Centre, University Hospital, University of Western Ontario, London, Ontario, Canada, and Department of Clinical Neurological Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada, London, ON, Canada  Neurology Center of San Antonio, San Antonio, Texas, San Antonio, TX  Medical College of Wisconsin, Milwaukee, Wisconsin, Milwaukee, WI  Alabama Neurology Associates, Birmingham, Alabama, Birmingham, AL  Hope Neurology MS Center, Knoxville, Tennessee, Knoxville, TN  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Bristol Myers Squibb, Princeton, New Jersey , Princeton, NJ  Kessler Foundation, West Orange, New Jersey, and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers - New Jersey Medical School, Newark, New Jersey, West Orange, NJ